CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Astrazeneca (AZN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target ...

For the first half of the fiscal year, analysts anticipate organic sales growth of 0.5%, net sales of $10.7bn and a 2% ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

Great Diamond Partners LLC decreased its position in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.2% during the ...

Mediolanum International Funds Ltd decreased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 67.7% ...

Indian stock markets closed the special trading session on account of the Union Budget 2025-26 on a flat note. The Nifty 50 closed the session 13.45 points, or 0.06%, lower at 23,494.95. The Sensex ...

Jon Smith talks through the implications of the latest AI news and flags up some FTSE shares that could benefit from the ...

Nvidia was rising early Friday as politicians and Big Tech firms comment on the effects of Chinese firm DeepSeek’s apparently low-cost AI.

AstraZeneca Plc abandoned plans to invest £450 million ($558 million) in a UK vaccine manufacturing plant, following protracted wrangling with the new Labour government over the level of state funding ...